Dr. Earle Burgess on the next steps with PARP inhibitors in prostate cancer

Earle Burgess, MD, associate professor of medicine, Levine Cancer Institute, Atrium Health, shares his expertise on what the next steps should be with PARP inhibitors in prostate cancer. The PARP inhibitors olaparib (Lynparza) and rucaparib (Rubraca) are approved by the FDA for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC), and other PARP agents are moving through the pipeline.